LabGenomics Co., Ltd. (KOSDAQ: 084650)
South Korea
· Delayed Price · Currency is KRW
2,450.00
-90.00 (-3.54%)
Dec 20, 2024, 9:00 AM KST
LabGenomics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Operating Revenue | 85,817 | 72,835 | 144,573 | 202,289 | 119,369 | 33,175 |
Other Revenue | 0 | 291.33 | 199.59 | 117.98 | 109.43 | - |
Revenue | 85,817 | 73,127 | 144,773 | 202,407 | 119,478 | 33,175 |
Revenue Growth (YoY) | 22.86% | -49.49% | -28.47% | 69.41% | 260.14% | - |
Cost of Revenue | 56,533 | 41,598 | 48,652 | 77,521 | 48,159 | 20,227 |
Gross Profit | 29,283 | 31,528 | 96,121 | 124,886 | 71,319 | 12,948 |
Selling, General & Admin | 40,054 | 30,104 | 25,996 | 18,518 | 14,686 | 10,398 |
Research & Development | 3,257 | 2,812 | 1,865 | 556.87 | - | - |
Other Operating Expenses | 541.01 | 667.32 | 591.29 | 361.38 | 332.68 | 298.49 |
Operating Expenses | 51,979 | 38,322 | 29,915 | 20,368 | 16,413 | 11,866 |
Operating Income | -22,696 | -6,794 | 66,206 | 104,518 | 54,906 | 1,082 |
Interest Expense | -5,244 | -4,969 | -573.97 | -208.03 | -223.8 | -415.79 |
Interest & Investment Income | 2,802 | 4,565 | 1,111 | 154.71 | 111.28 | 292.98 |
Earnings From Equity Investments | -1,120 | -1,969 | -72.11 | -46.37 | -22.1 | -274.33 |
Currency Exchange Gain (Loss) | -140.05 | 1,215 | 1,145 | 2,146 | -1,171 | -12.98 |
Other Non Operating Income (Expenses) | -3,342 | -1,447 | -448.52 | 90.13 | 128.96 | 444.22 |
EBT Excluding Unusual Items | -29,740 | -9,399 | 67,367 | 106,655 | 53,729 | 1,116 |
Gain (Loss) on Sale of Investments | 5,042 | 1,016 | -3,929 | 2,531 | -268.91 | 253.8 |
Gain (Loss) on Sale of Assets | -300.06 | 1,299 | -44.62 | 0.9 | - | 11.61 |
Asset Writedown | - | - | - | -55.2 | -1,636 | -306.41 |
Other Unusual Items | - | - | - | - | -1.75 | - |
Pretax Income | -24,998 | -7,085 | 63,393 | 109,132 | 51,822 | 1,075 |
Income Tax Expense | -2,299 | -1,839 | 15,467 | 25,277 | 9,058 | 112.86 |
Earnings From Continuing Operations | -22,699 | -5,246 | 47,926 | 83,855 | 42,764 | 962.42 |
Minority Interest in Earnings | 363.32 | 571.89 | 471.27 | - | 2.91 | - |
Net Income | -22,336 | -4,674 | 48,397 | 83,855 | 42,766 | 962.42 |
Net Income to Common | -22,336 | -4,674 | 48,397 | 83,855 | 42,766 | 962.42 |
Net Income Growth | - | - | -42.28% | 96.08% | 4343.63% | - |
Shares Outstanding (Basic) | 74 | 74 | 68 | 68 | 66 | 62 |
Shares Outstanding (Diluted) | 74 | 74 | 68 | 68 | 66 | 62 |
Shares Change (YoY) | 2.54% | 9.17% | 0.20% | 2.61% | 6.06% | - |
EPS (Basic) | -300.93 | -63.22 | 714.67 | 1240.72 | 649.30 | 15.50 |
EPS (Diluted) | -301.36 | -63.22 | 714.50 | 1240.50 | 649.30 | 15.50 |
EPS Growth | - | - | -42.40% | 91.05% | 4089.83% | - |
Free Cash Flow | -8,528 | -8,817 | 31,307 | 51,645 | 45,673 | 2,627 |
Free Cash Flow Per Share | -114.90 | -119.26 | 462.30 | 764.15 | 693.42 | 42.30 |
Gross Margin | 34.12% | 43.11% | 66.39% | 61.70% | 59.69% | 39.03% |
Operating Margin | -26.45% | -9.29% | 45.73% | 51.64% | 45.95% | 3.26% |
Profit Margin | -26.03% | -6.39% | 33.43% | 41.43% | 35.79% | 2.90% |
Free Cash Flow Margin | -9.94% | -12.06% | 21.62% | 25.52% | 38.23% | 7.92% |
EBITDA | -13,044 | -897.7 | 70,171 | 107,858 | 58,333 | 4,885 |
EBITDA Margin | -15.20% | -1.23% | 48.47% | 53.29% | 48.82% | 14.72% |
D&A For EBITDA | 9,652 | 5,896 | 3,965 | 3,340 | 3,427 | 3,803 |
EBIT | -22,696 | -6,794 | 66,206 | 104,518 | 54,906 | 1,082 |
EBIT Margin | -26.45% | -9.29% | 45.73% | 51.64% | 45.95% | 3.26% |
Effective Tax Rate | - | - | 24.40% | 23.16% | 17.48% | 10.50% |
Advertising Expenses | - | 80.68 | 100.91 | 74.86 | 31.5 | 46.36 |
Source: S&P Capital IQ. Standard template. Financial Sources.